Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abbas-Aghababazadeh F, Lu P, Fridley BL (2019) Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines. Sci Rep 9:14421. https://doi.org/10.1038/s41598-019-50936-0
Alagumuthu M, Arumugam S (2017) Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents. Cancer Chemother Pharmacol 79(2):389–397
Amin KM, Syam YM, Anwar MM, Ali HI, Abdel-Ghani TM, Serry AM (2017) Synthesis and molecular docking studies of new furochromone derivatives as p38alpha MAPK inhibitors targeting human breast cancer MCF-7 cells. Bioorg Med Chem 25(8):2423–2436. https://doi.org/10.1016/j.bmc.2017.02.065
Andreeva OV, Garifullin BF, Sharipova RR, Strobykina IY, Sapunova AS, Voloshina AD, Belenok MG, Dobrynin AB, Khabibulina LR, Kataev VE (2020) Glycosides and glycoconjugates of the diterpenoid isosteviol with a 1,2,3-triazolyl moiety: Synthesis and cytotoxicity evaluation. J Nat Prod 83(8):2367–2380. https://doi.org/10.1021/acs.jnatprod.0c00134
Attia MH, Elrazaz EZ, El-Emam SZ, Taher AT, Abdel-Aziz HA, Abouzid KAM (2020) Synthesis and in-vitro anti-proliferative evaluation of some pyrazolo [1,5-a]pyrimidines as novel larotrectinib analogs. Bioorg Chem 94:103458. https://doi.org/10.1016/j.bioorg.2019.103458
Awasthee N, Rai V, Chava S, Nallasamy P, Kunnumakkara AB, Bishayee A, Chauhan SC, Challagundla KB, Gupta SC (2019) Targeting I kappa appaB kinases for cancer therapy. Sem Cancer Biol 56:12–24. https://doi.org/10.1016/j.semcancer.2018.02.007
Bae SY, Guan N, Yan R, Warner K, Taylor SD, Meyer AS (2020) Measurement and models accounting for cell death capture hidden variation in compound response. Cell Death Dis 11(4):255. https://doi.org/10.1038/s41419-020-2462-8
Bhardwaj VK, Purohit R (2021) Targeting the protein-protein interface pocket of Aurora-A-TPX2 complex: rational drug design and validation. J Biomol Struct Dyn 39(11):3882–3891. https://doi.org/10.1080/07391102.2020.1772109
Boraei ATA, Gomaa MS, El Ashry ESH, Duerkop A (2017) Design, selective alkylation and X-ray crystal structure determination of dihydro-indolyl-1,2,4-triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents. Eur J Med Chem 125:360–371. https://doi.org/10.1016/j.ejmech.2016.09.046
Brady R, Enderling H (2019) Mathematical models of cancer: when to predict novel therapies, and when not to. Bull Math Biol 81(10):3722–3731. https://doi.org/10.1007/s11538-019-00640-x
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018 Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68(6):394–424. https://doi.org/10.3322/caac.21492
Brooks EA, Galarza S, Gencoglu MF, Cornelison RC, Munson JM, Peyton SR (2019) Applicability of drug response metrics for cancer studies using biomaterials. Philos Trans R Soc B 374(1779):20180226. https://doi.org/10.1098/rstb.2018.0226
Burnham KP, Anderson DR (2002) Model selection and multimodel inference: a practical information-theoretic approach, 2nd edn. Springer, New York
Calhelha RC, Martínez MA, Isabel MAP, Ferreira CFR (2017) Mathematical models of cytotoxic effects in endpoint tumor cell line assays: critical assessment of the application of a single parametric value as a standard criterion to quantify the dose-response effects and new unexplored proposal formats. Analyst 142:4124–4141. https://doi.org/10.1039/c7an00782e
Chen B, Dong JQ, Pan W-J, Ruiz A (2012) Pharmacokinetics/pharmacodynamics model-supported early drug development. Curr Pharm Biotechnol 13(7):1360–1375. https://doi.org/10.2174/138920112800624436
Choi YH, Zhang C, Liu Z, Tu M-J, Yu A-X, Yu A-M (2021) A novel integrated pharmacokinetic-pharmacodynamic model to evaluate combination therapy and determine in vivo synergisms. J Pharmacol Exp Ther 377(3):305–315. https://doi.org/10.1124/jpet.121.000584
Chrysanthopoulou SA, Rutter CM, Gatsonis CA (2021) Bayesian versus empirical calibration of microsimulation models: a comparative analysis. Med Dec Making 41(6):714–726. https://doi.org/10.1177/0272989X211009161
de Witte WEA, Wong YC, Nederpelt I, Heitman LH, Danhof M, van der Graaf PH, Gilissen RAHJ, de Lange ECM (2016) Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients. Exp Opin Drug Discov 11(1):45–63. https://doi.org/10.1517/17460441.2016.1100163
Eisenberg MC, Jain HV (2017) A confidence building exercise in data and identifiability: modeling cancer chemotherapy as a case study. J Theor Biol 437:63–78. https://doi.org/10.1016/j.jtbi.2017.07.018
Evans ND, Cheung SYA, Yates JWT (2018) Structural identifiability for mathematical pharmacology: models of myelosuppression. J Pharmacokin Pharmacodyn 45(1):79–90. https://doi.org/10.1007/s10928-018-9569-x
Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW (2013) Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 9(11):708. https://doi.org/10.1038/NCHEMBIO.1337
Frieler M, Pho C, Lee B, Dobrovolny HM, Naumov A, Akkaraju G (2021) Effects of doxorubicin delivery by nitrogen-doped graphene quantum dots on cancer cell growth: experimental study and mathematical modeling. Nanomaterials 11:140. https://doi.org/10.3390/nano11010140
Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ (2019) Individualized empiric vancomycin dosing in neonates using a model-based approach. J Ped Infect Dis Soc 8(2):97–104. https://doi.org/10.1093/jpids/pix109
Gabr MT, El-Gohary NS, El-Bendary ER, El-Kerdawy MM, Ni N (2016) Synthesis, in vitro antitumor activity and molecular modeling studies of a new series of benzothiazole Schiff bases. Chin Chem Lett 27(3):380–386. https://doi.org/10.1016/j.cclet.2015.12.033
Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF (2019) Translational framework predicting tumour response in gemcitabine-treated patients with advanced pancreatic and ovarian cancer from xenograft studies. AAPS J 21(2):23. https://doi.org/10.1208/s12248-018-0291-9
Gerlee P (2013) The model muddle: in search of tumor growth laws. Cancer Res 73(8):2407–2411. https://doi.org/10.1158/0008-5472.CAN-12-4355
Gupta A, Gautam P, Wennerberg K, Aittokallio T (2020) A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Commun Biol 3(1):42. https://doi.org/10.1038/s42003-020-0765-z
Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86(8):1297–1302. https://doi.org/10.1038/sj.bjc.6600139
Hafner M, Niepel M, Chung M, Sorger PK (2016) Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods 13(6):521. https://doi.org/10.1038/NMETH.3853
Harris LA, Frick PL, Garbett SP, Hardeman KN, Paudel BB, Lopez CF, Quaranta V, Tyson DR (2016) An unbiased metric of antiproliferative drug effect in vitro. Nat Methods 13(6):497–502. https://doi.org/10.1038/nMeth.3852
Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6(6):429–453
Kazan HH, Urfali-Mamatoglu C, Yalcin GD, Bulut O, Sezer A, Banerjee S, Gunduz U (2020) 15-LOX-1 has diverse roles in the resensitization of resistant cancer cell lines to doxorubicin. J Cell Physiol 235(5):4965–4978. https://doi.org/10.1002/jcp.29375
Kerioui M, Mercier F, Bertrand J, Tardivon C, Bruno R, Guedj J, Desmee S (2020) Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. Stat Med 39(30):4853–4868. https://doi.org/10.1002/sim.8756
Khan AU, Khan M, Cho MH, Khan MM (2020) Optimization of chemotherapy and immunotherapy: in silico analysis using pharmacokinetic-pharmacodynamic and tumor growth models. Bioprocess Biosys Eng. https://doi.org/10.1007/s00449-020-02330-8
Khan FM, Saleh E, Alawadhi H, Harati R, Zimmermann W-H, El-Awady R (2018) Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin. Cancer Biol Ther 19(1):25–33. https://doi.org/10.1080/15384047.2017.1394544
Kuete V, Omosa LK, Tala VRS, Midiwo JO, Mbaveng AT, Swaleh S, Karaosmanoglu O, Sivas H (2016) Cytotoxicity of plumbagin, rapanone and 12 other naturally occurring quinones from kenyan flora towards human carcinoma cells. BMC Pharmacol Toxicol 17:60. https://doi.org/10.1186/s40360-016-0104-7
Kurilov R, Haibe-Kains B, Brors B (2020) Assessment of modelling strategies for drug response prediction in cell lines and xenografts. Sci Rep 10(1):2849. https://doi.org/10.1038/s41598-020-59656-2
Larsson P, Engqvist H, Biermann J, Ronnerman EW, Forssell-Aronsson E, Kovacs A, Karlsson P, Helou K, Parris TZ (2020) Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens. Sci Rep 10(1):5798. https://doi.org/10.1038/s41598-020-62848-5
Marouille AL, Petit E, Kaderbhai C, Desmoulins I, Hennequin A, Mayeur D, Fumet J-D, Ladoire S, Tharin Z, Ayati S, Royer Ilie S, Schmitt AB (2021) Pharmacokinetic/pharmacodynamic model of neutropenia in real-life palbociclib-treated patients. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13101708
Meredith A-M, Dass CR (2016) Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol 68(6):729–741. https://doi.org/10.1111/jphp.12539
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. Cancer J Clin 66(4):271–289. https://doi.org/10.3322/caac.21349
Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG (2019) Therapeutic targeting of trained immunity. Nat Rev Drug Discov 18(7):553–566. https://doi.org/10.1038/s41573-019-0025-4
Murphy H, McCarthy G, Dobrovolny HM (2016) Differences in predictions of ode models of tumor growth: a cautionary example. BMC Cancer 16:163. https://doi.org/10.1186/s12885-016-2164-x
Murphy H, Jaafari H, Dobrovolny HM (2020) Understanding the effect of measurement time on drug characterization. Plos One 15(5):0233031. https://doi.org/10.1371/journal.pone.0233031
Nayak S, Sander O, Al-Huniti N, de Alwis D, Chain A, Chenel M, Sunkaraneni S, Agrawal S, Gupta N, Visser SAG (2018) Getting innovative therapies faster to patients at the right dose: Impact of quantitative pharmacology towards first registration and expanding therapeutic use. Clin. Pharmacol. Therapeut. 103(3):378–383. https://doi.org/10.1002/cpt.978
Niepel M, Hafner M, Mills CE, Subramanian K, Williams EH, Chung M, Gaudio B, Barrette AM, Stern AD, Hu B, Korkola JE, Gray JW, Birtwistle MR, Heiser LM, Sorger PK, Shamu CE, Jayaraman G, Azeloglu EU, Iyengar R, Sobie EA, Mills GB, Liby T, Jaffe JD, Alimova M, Davison D, Lu X, Golub TR, Subramanian A, Shelley B, Svendsen CN, Ma’ayan A, Medvedovic M (2019) A multi-center study on the reproducibility of drug-response assays in mammalian cell lines. Cell Syst 9(1):35. https://doi.org/10.1016/j.cels.2019.06.005
Paredes Bonilla RV, Nekka F, Craig M (2021) Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy. Pharmacology 106(9–10):542–550. https://doi.org/10.1159/000518037
Peng T, Deng Z, He J, Li Y, Tan Y, Peng Y, Wang X-Q, Tan W (2020) Functional nucleic acids for cancer theranostics. Coord. Chem. Rev. 403:213080. https://doi.org/10.1016/j.ccr.2019.213080
Phutdhawong W, Chuenchid A, Taechowisan T, Sirirak J, Phutdhawong WS (2021) Synthesis and biological activity evaluation of coumarin-3-carboxamide derivatives. Molecules 26(6):1653. https://doi.org/10.3390/molecules26061653
Raue A, Kreutz C, Maiwald T, Bachmann J, Schilling M, Klingmüller U, Timmer J (2009) Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics 25(15):1923–1929
Rejinold NS, Choi G, Choy J-H (2020) Recent trends in nano photo-chemo therapy approaches and future scopes. Coord Chem Rev 411:213252. https://doi.org/10.1016/j.ccr.2020.213252
Robledo-Cadena DX, Gallardo-Perez JC, Davila-Borja V, Pacheco-Velazquez SC, Belmont-Diaz JA, Ralph SJ, Blanco-Carpintero BA, Moreno-Sanchez R, Rodriguez-Enriquez S (2020) Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals 13(12):463. https://doi.org/10.3390/ph13120463
Roskoski R (2019) Properties of FDA-approved small molecule protein kinase inhibitors. Pharm Res 144:19–50. https://doi.org/10.1016/j.phrs.2019.03.006
Rutter CM, Miglioretti DL, Savarino JE (2009) Bayesian calibration of microsimulation models. J Am Stat Assoc 104(488):1338–1350. https://doi.org/10.1198/jasa.2009.ap07466
Salem MS, Ali MAM (2016) Novel pyrazolo[3,4-b]pyridine derivatives: Synthesis, characterization, antimicrobial and antiproliferative profile. Biol Pharmaceut Bull 39(4):473–483
Salo-Ahen OMH, Alanko I, Bhadane R, Bonvin AMJJ, Honorato RV, Hossain S, Juffer AH, Kabedev A, Lahtela-Kakkonen M, Larsen AS, Lescrinier E, Marimuthu P, Mirza MU, Mustafa G, Nunes-Alves A, Pantsar T, Saadabadi A, Singaravelu K (2021) Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9(1):71. https://doi.org/10.3390/pr9010071
Schuetz DA, de Witte WEA, Wong YC, Knasmueller B, Richter L, Kokh DB, Sadiq SK, Bosma R, Nederpelt I, Heitman LH, Segala E, Amaral M, Guo D, Andres D, Georgi V, Stoddart LA, Hill S, Cooke RM, De Graaf C, Leurs R, Frech M, Wade RC (2017) Kinetics for drug discovery: an industry-driven effort to target drug residence time. Drug Discov Today 22(6):896–911. https://doi.org/10.1016/j.drudis.2017.02.002
Sharpe S, Dobrovolny HM (2021) Predicting the effectiveness of chemotherapy using stochastic ODE models of tumor growth. Commun Nonlinear Sci Numer Simul 101:105883. https://doi.org/10.1016/j.cnsns.2021.105883
Singh R, Bhardwaj VK, Sharma J, Das P, Purohit R (2021) Identification of selective cyclin-dependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: an in silico exploration. J Biomol Struct Dyn 318:1–9. https://doi.org/10.1080/07391102.2021.1900918
Sritharan S, Sivalingam N (2021) A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci 278:119527. https://doi.org/10.1016/j.lfs.2021.119527
Tang W, Zhao G (2020) Small molecules targeting HIF-1 alpha pathway for cancer therapy in recent years. Bioorg Mol Chem 28(2):115235. https://doi.org/10.1016/j.bmc.2019.115235
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogen Genom 21(7):440–446. https://doi.org/10.1097/FPC.0b013e32833ffb56
Verhulst P-F (1838) Notice sur la loi que la population poursuit dans son accroissement. Corr Math Phys 10:113–121
Wang D, Hensman J, Kutkaite G, Toh TS, Galhoz A, Dry JR, Saez-Rodriguez J, Garnett MJ, Menden MP, Dondelinger F (2021) A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates. eLife 9:60352. https://doi.org/10.7554/eLife.60352
Wu Z, Phan T, Baez J, Kuang Y, Kostelich EJ (2019) Predictability and identifiability assessment of models for prostate cancer under androgen suppression therapy. Math Biosci Eng 16(5):3512–3536. https://doi.org/10.3934/mbe.2019176